The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...

By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide ...

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got ...

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

AI is no longer a distant concept; it is reshaping industries today. For pharmaceutical companies, the question is clear: how ...

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

In a drastic decision made outside of its typical review process, the agency declared it would recommend 11 childhood shots ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear ...

With the rise of biologics, precision medicine and AI-driven drug discovery, clinical research has entered a new and complex ...